See the DrugPatentWatch profile for Emgality
Emgality, a medication used to prevent migraine, is anticipated to generate significant sales in 2024. Eli Lilly, the manufacturer, reported that Emgality’s sales reached $699.5 million in 2023 [1]. The company has projected strong growth for its neuroscience portfolio, which includes Emgality [2].
How much did Emgality make in previous years?
Before 2023, Emgality’s sales were $634.6 million in 2022 and $535.6 million in 2021 [1]. This indicates a consistent upward trend in its market performance [1].
What is Emgality used for?
Emgality is prescribed for the preventive treatment of episodic migraine in adults [3]. It is also used for the treatment of acute migraine in adults [3].
When does Emgality's patent expire?
The patent landscape for Emgality involves multiple patents. According to DrugPatentWatch.com, the earliest anticipated patent expiry date for Emgality is in 2029, with later expirations extending into the 2030s [4]. Specific details regarding patent challenges or extensions could influence market exclusivity [4].
Are there similar drugs to Emgality?
Emgality belongs to a class of drugs known as CGRP inhibitors, which target calcitonin gene-related peptide to prevent or treat migraines. Other medications in this class include Aimovig (erenumab), Ajovy (fremanezumab), and Vyepti (eptinezumab) [5]. These drugs offer alternative treatment options for migraine prevention and treatment.
What are the sales projections for Eli Lilly's neuroscience drugs?
Eli Lilly has highlighted its neuroscience products, including Emgality, as key drivers of future growth [2]. The company's strategic focus on this therapeutic area suggests continued investment and marketing support for Emgality, likely contributing to its projected sales performance in 2024 and beyond [2].
Sources:
[1] https://investor.lilly.com/financial-reports/annual-reports
[2] https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-reports-fourth-quarter-and-full-year-2023-results
[3] https://www.emgality.com/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788268/